Omnicell (OMCL) shares surged nearly 14% after the company reported Q3 results that significantly surpassed analyst estimates for both revenue and non-GAAP EPS, despite a slight year-over-year decline in adjusted profitability. The healthcare technology firm posted $311 million in revenue, a 10% year-over-year increase, and non-GAAP EPS of $0.51, attributing growth to foundational point-of-care connected devices and technical services. Management subsequently raised its full-year revenue guidance to $1.18-$1.19 billion and provided 2025 adjusted EPS guidance of $1.63-$1.73, indicating a positive outlook.
Omnicell (OMCL) reported a robust third-quarter performance, significantly surpassing analyst estimates for both revenue and non-GAAP earnings per share, which propelled its stock to an almost 14% gain on Thursday, outperforming the S&P 500's 1% decline. This strong market reaction underscores investor confidence in the company's operational execution despite broader market headwinds. The healthcare technology firm posted Q3 revenue of $311 million, marking a 10% year-over-year increase and exceeding analyst expectations of under $296 million. Non-GAAP net income, while slightly lower year-over-year at $24 million ($0.51 per share), still comfortably beat the $0.36 per share consensus, driven by foundational point-of-care connected devices and technical services. Management's positive outlook is further evidenced by the raised full-year revenue guidance to a range of $1.18 billion to $1.19 billion. Additionally, the company initiated 2025 adjusted earnings per share guidance of $1.63 to $1.73, signaling continued growth momentum and operational efficiency into the next fiscal year.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
